Introduction {#section1-2192568217694016}
============

Up to 70% of patients with malignancies are found to have skeletal involvement at postmortem examination, with the spine being the most common location.^[@bibr1-2192568217694016],[@bibr2-2192568217694016]^ When left untreated, spinal metastases may cause axial pain, vertebral body fracture, radiculopathy, and the most debilitating complication of metastatic epidural spinal cord compression (MESCC). Within the context of advances in systemic therapy, including targeted therapy and immunotherapy, survival in subgroups of patients with metastatic disease is being prolonged far greater than previously expected.^[@bibr3-2192568217694016][@bibr4-2192568217694016][@bibr5-2192568217694016][@bibr6-2192568217694016]--[@bibr7-2192568217694016]^ Coincidentally, advances in image-guided external beam radiation have given rise to stereotactic body radiotherapy (SBRT) that allows for high doses of radiation to be delivered in a few fractions. According to the Canadian Association of Radiation Oncology task force, SBRT has been defined as"the precise delivery of highly conformal and image-guided hypofractionated external beam radiotherapy, delivered in a single or few fraction(s), to an extracranial body target with doses at least biologically equivalent to a radical course when given over a protracted conventionally (1.8-3.0 Gy/fraction) fractionated schedule."^[@bibr8-2192568217694016](p630)^"SBRT is effective in providing adequate local disease control in combination with surgery or as a sole treatment in carefully selected cases. Therefore, it has become the treatment of choice when complete local ablation of a metastatic lesion is indicated. This paradigm shift in the management of patients with metastatic disease is best observed in the patient with oligometastatic disease. This distinct intermediate entity between localized disease and widespread malignant dissemination typically allows for no more than 5 sites of metastases, and the data suggests adequate disease control at 2 to 5 years in approximately 20% of these patients when all sites have been treated with effective ablative therapy.^[@bibr9-2192568217694016],[@bibr10-2192568217694016]^

Application of SBRT to the treatment of spinal oncological lesions has been a relatively late advance due to the complex relationship between the vertebral segment and adjacent critical structures such as the spinal cord, esophagus, and bowel. In particular, radiation myelopathy has been a major concern as little was known about spinal cord tolerance with high doses per fraction radiation and the stringent technical requirements required to ensure the highest level of precision.^[@bibr11-2192568217694016][@bibr12-2192568217694016][@bibr13-2192568217694016]--[@bibr14-2192568217694016]^ Ultimately, sufficient clinical experience and guidelines are now available to direct appropriate practice.^[@bibr8-2192568217694016],[@bibr15-2192568217694016][@bibr16-2192568217694016][@bibr17-2192568217694016]--[@bibr18-2192568217694016]^ As a result, spine SBRT is currently being practiced as an alternative to conventional palliative radiation in primary treatment, re-irradiation, and in the postoperative setting, albeit without randomized trials to support practice. Furthermore, we now have a greater understanding of the limitations of spine SBRT, as well as the potential complications and the challenges associated with response determination. This article provides a technical review of spine SBRT planning and delivery, indications for treatment, outcomes with a focus on patterns of failure and the importance of epidural disease, complications including vertebral compression fractures (VCF), and the challenges of response assessment. Moreover, the surgical approach to spinal metastases is discussed with an overview of emerging minimally invasive techniques.

Spine SBRT Planning and Delivery {#section2-2192568217694016}
--------------------------------

SBRT has been made possible in recent years due to advances in patient immobilization, target visualization, and delivery methods including image guidance. The challenge lies in creating complex dose distributions due to the inherent irregularity of the vertebral segment and the proximity of the organs-at-risk, which have to be underdosed relative to the target to respect radiation tolerance. Typically, a threshold of less than 5% risk of serious adverse effects is chosen. The first step in planning spine SBRT is immobilizing the patient in a near-rigid body frame for the treatment planning computed tomography (CT) scan. Data has shown that using the BodyFIX (Elekta AB, Stockholm, Sweden) device increases the reproducibility of patient positioning during treatment delivery to within 1.2 mm and 0.9° with 95% confidence.^[@bibr19-2192568217694016]^ An example of a patient immobilized in a BodyFIX device on the treatment couch is illustrated in [Figure 1](#fig1-2192568217694016){ref-type="fig"}. The importance of bulk patient motion was shown in a recent magnetic resonance imaging (MRI)-based analysis of spinal cord motion.^[@bibr20-2192568217694016]^ The study, which acquired data over a 137-second time frame, found the median physiologic motion of the spinal cord itself to be less than 0.5 mm in all directions. This component of motion was relatively minor compared to the gross patient motion without immobilization, which demonstrated maximal statistically significant displacements of 2.21 mm, 2.87 mm, and 3.90 mm in the anteroposterior, lateral, and superior-inferior planes, respectively. The next step in spine SBRT planning involves acquisition of volumetric thin-slice axial T1 and T2 non--contrast-enhanced MRIs, including the target vertebral segment and at least one vertebral body above and below, which are fused to the treatment planning CT for delineation of the clinical target volume in accordance with the International Spine Research Consortium recommendations. In the event of prior surgery where presence of spinal hardware results in significant ferromagnetic artifacts obscuring the spinal cord, a CT myelogram may be performed just prior to the immobilization step.

![An example of a spine SBRT immobilization device with a patient shown in the BodyFIX system (Elekta AB, Stockholm, Sweden). The device consists of a vacuum cushion, a clear plastic cover sheet, and a dual vacuum pump that maintains a vacuum seal over the top of the patient with the cover sheet molded to the body contours. Precise adjustments of the patient position may be made with the robotic couch, which permits both translational and rotational corrections (6 degrees of freedom).](10.1177_2192568217694016-fig1){#fig1-2192568217694016}

Appreciation for the approach to target volume delineation is critical in spine SBRT. The tumor is generally defined on CT, and MRI is used to assist in visualizing and delineating relevant anatomy at risk. This approach has been outlined in detail in the consensus guidelines published by International Spine Research Consortium, whereby the target is defined by the clinical target volume, which includes a bony margin around the radiologically visible tumor, and the gross tumor volume, to encompass microscopic subclinical disease. In general, the entire vertebral body is included if any portion of the vertebral body is involved. Inclusion of the pedicle, transverse process, and lamina is recommended if any of these regions are involved. The spinous process should be included within the target volume if the lamina or the spinous process itself is involved. With respect to epidural disease, a 5 mm margin is typically applied within the epidural space respecting the spinal cord and added cranio-caudally. In the postoperative setting, practice may be guided by a recent detailed analysis of patterns of epidural progression following postoperative spine SBRT.^[@bibr21-2192568217694016]^ The authors analyzed 25 spine SBRT cases with preoperative epidural disease with subsequent epidural disease progression after postoperative SBRT. The location of epidural disease in this study was categorized based on dividing the vertebral anatomy into 6 sectors (anterior compartment: vertebral body and anterior epidural space, left and right pedicles and associated epidural space; posterior compartment: left and right transverse processes and laminae and associated epidural space, spinous process, and associated epidural space). It was demonstrated that postoperative MRI epidural disease location alone is insufficient in determining the appropriate target volume for the purposes of SBRT planning, and taking into account the preoperative disease location is critical. An epidural-sparing horseshoe-type clinical target volume may only be appropriate for cases where epidural disease is confined to the anterior aspect on both pre- and postoperative imaging. In other scenarios, a donut-shaped distribution where the entire epidural space is covered circumferentially may be more prudent.

The ideal dose fractionation for spine SBRT in the setting of metastases is at present uncertain. Common practice includes 18 to 24 Gy in 1 fraction, 24 Gy in 2 fractions, 24 to 30 Gy in 3 fractions, 30 Gy in 4 fractions, and 30 to 40 Gy in 5 fractions. Exposing tumors to a dose per fraction of 8 Gy or higher may activate new radiobiological pathways leading to tumor cell death through mechanisms apart from mitotic catastrophe and apoptosis, the dominant forms of cell death in most tumor histologies when irradiated with conventional fractionation (1.8-2 Gy per fraction). Proposed mechanisms of increased cell death in SBRT include radiation-induced tumor-antigen specific immune response, endothelial/vascular injury, or simply increased cell kill secondary to higher delivered dose.^[@bibr22-2192568217694016][@bibr23-2192568217694016][@bibr24-2192568217694016][@bibr25-2192568217694016][@bibr26-2192568217694016][@bibr27-2192568217694016][@bibr28-2192568217694016][@bibr29-2192568217694016]--[@bibr30-2192568217694016]^ Currently, there are no dose finding randomized trials to confirm the superiority of single-fraction SBRT as compared to multiple-fraction SBRT to make a recommendation. At the University of Toronto, the preferred treatment regimen is 24 Gy in 2 fractions in order to maintain a risk of VCF to approximately 10%. In the scenario of very large tumors or cases that have been heavily irradiated previously, 30 Gy in 4 fractions is typically favored.

Spine SBRT Indications and Approach to Patient Evaluation {#section3-2192568217694016}
---------------------------------------------------------

The appropriate assessment and management of spinal metastases requires a multidisciplinary approach consisting of radiation oncology, spine surgery, medical oncology, and radiology. Treatment decision-making is a complex process that involve considerations for (1) patient factors including neurological function, presence and severity of pain, age, comorbidities, performance status, estimated life expectancy, and patient preferences; (2) oncologic factors including the tumor histology and molecular characteristics, overall disease burden, and systemic therapeutic options; and (3) treatment-specific factors including the spinal location/level, presence and grade of epidural disease, radiographic appearance, prior surgical or radiation treatment, and degree of spinal instability.

Both the Tomita and Tokuhashi scoring systems were developed for preoperative prognostic evaluation of spinal metastases; however, these systems were devised prior to the availability of spine SBRT and minimally invasive surgical techniques.^[@bibr31-2192568217694016],[@bibr32-2192568217694016]^ Furthermore, as the patient population with spinal metastases is highly heterogeneous, the ability to predict survival with these simple scoring system has been questioned.^[@bibr33-2192568217694016],[@bibr34-2192568217694016]^ More recently, the NOMS (Neurologic, Oncologic, Mechanical Instability, Systemic Disease) decision framework was developed to highlight modern principles specific to spine oncology.^[@bibr35-2192568217694016]^ For the purposes of this review, we have summarized our decision-making framework, which takes into account the relevant literature in [Table 1](#table1-2192568217694016){ref-type="table"}, and this can guide practitioners as to the suitability for spine SBRT.

###### 

Approach to Assessment of Suitability for Spine SBRT.

![](10.1177_2192568217694016-table1)

  Factors               Suitable                                                            Cautionary                                Unsuitable
  --------------------- ------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------
  Patient                                                                                                                             
   Performance status   ECOG 0-2                                                                                                      ECOG ≥3
   Life expectancy      ≥3 months                                                                                                     
   Pain                 Intractable                                                                                                   
   Neurologic                                                                                                                         Symptomatic cord compression or cauda equina syndrome
  Oncologic                                                                                                                           
   Disease burden       Oligometastatic disease                                             Widespread, rapidly progressive disease   
   Tumor histology      Histological proof of malignancy                                    Radiosensitive (eg, myeloma, lymphoma)    
   Systemic therapy     Systemic therapeutic options available or indolent disease course                                             
  Treatment                                                                                                                           
   Imaging              ESCC (Bilsky) grade 0-1                                             ESCC (Bilsky) grade 2                     ESCC (Bilsky) grade 3 or cauda equina compressions
                        Up to 3 contiguous or noncontiguous levels                                                                    \>3 contiguous or noncontiguous levels
   Spinal stability     SINS 0-6                                                            SINS 7-12                                 SINS 13-18
   Prior radiation      Previous cEBRT to affected level                                    Previous SBRT to affected level           Previous EBRT to affected level within 90 days or systemic radionuclide within 30 days
   Positioning                                                                                                                        Inability to tolerate near-rigid body immobilization

Abbreviations: SBRT, stereotactic body radiotherapy; ECOG, Eastern Cooperative Oncology Group; ESCC, epidural spinal cord compression; SINS, Spinal Instability Neoplastic Score; EBRT, external beam radiotherapy; cEBRT, conventional EBRT.

Special Situations {#section4-2192568217694016}
------------------

Patients with mechanical instability of the spine should be reviewed with a spinal surgeon for stabilization as SBRT does not address this problem. Identification of these patients may be challenging for many practitioners. Recently, Fisher and colleagues proposed a classification system known as the Spinal Instability Neoplastic Score (SINS) to evaluate the degree of spinal instability in patients with spinal metastatic disease.^[@bibr36-2192568217694016][@bibr37-2192568217694016]--[@bibr38-2192568217694016]^ This tool has been validated among spinal surgeons, radiation oncologists, and radiologists with respect to reliability. The SINS criteria are summarized in [Table 2](#table2-2192568217694016){ref-type="table"} and consist of classifying the involved spinal segment according to the location along the spinal axis, the presence of mechanical pain, and radiographic factors including the lesion type (lytic, blastic, mixed), spinal alignment, vertebral body collapse, and involvement of the posterior spinal elements. Each criterion is assigned a score and tallied to a total out of 18. A score of 0 to 6 indicates stability. In contrast, a score higher than 13 demonstrates frank instability and a score between 7 and 12 is in the indeterminate zone where there is potential instability. As SBRT does not address mechanical instability, a surgical consult is recommended for patients with a score ≥7. Moreover, SINS is increasingly being investigated for its predictive capacity for adverse events. Specifically, with respect to post-SBRT VCF, the presence of lytic disease, baseline fracture, and malalignment has been shown to be significant.^[@bibr39-2192568217694016]^ Other recent studies have demonstrated that a higher total score is predictive for increased spinal adverse events following conventional external beam radiation (cEBRT) and for symptomatic VCF after spine SBRT.^[@bibr40-2192568217694016],[@bibr41-2192568217694016]^

###### 

The Spinal Instability Neoplastic Score (SINS) criteria^[@bibr36-2192568217694016]^.

![](10.1177_2192568217694016-table2)

  SINS Criterion                                                                        Score^a^
  ------------------------------------------------------------------------------------- ----------
  Location                                                                              
   Junctional (occiput-C2, C7-T2, T11-L1, L5-S1)                                        3
   Mobile spine (C3-6, L2-L4)                                                           2
   Semirigid (T3-T10)                                                                   1
   Rigid (S2-S5)                                                                        0
  Pain                                                                                  
   Mechanical                                                                           3
   Occasional and non-mechanical                                                        1
   No pain                                                                              0
  Bone lesion type                                                                      
   Lytic                                                                                2
   Mixed (lytic and blastic)                                                            1
   Blastic                                                                              0
  Radiographic spinal alignment                                                         
   Subluxation/translation                                                              4
   Kyphosis/scoliosis                                                                   2
   Normal alignment                                                                     0
  Degree of vertebral body collapse or involvement                                      
   \>50% collapse                                                                       3
   \<50% collapse                                                                       2
   No collapse but with \>50% body involved                                             1
   None of the above                                                                    0
  Posterolateral involvement (fracture or replacement by tumor) of spinal elements^b^   
   Bilateral                                                                            3
   Unilateral                                                                           1
   None                                                                                 0

^a^Total score: 0 to 6, stability; 7t o 12, indeterminate (possibly impending) instability; 13 to 18, instability.

^b^Facet, pedicle, or costovertebral joint.

Aside from spinal instability, another group of patients warrant referral to a spine surgeon. Patients with symptomatic high-grade epidural disease should be considered for surgical circumferential decompression. In order to determine the extent of epidural disease, an MRI is required. Based on the imaging characteristics, a useful grading system was proposed by Bilsky and colleagues from the Spine Oncology Study Group. The Bilsky system classifies the degree of epidural spinal cord compression (ESCC) using a 6-point scale.^[@bibr42-2192568217694016]^ The system was modified from an original 4-point scale to further define the varying extent of epidural impingement for the purposes of spine SBRT. In the ESCC scale, grade 0 denotes bone-only disease, grade 1a denotes epidural impingement without deformation of the thecal sac, grade 1b denotes deformation of the thecal sac but without spinal cord abutment, grade 1c denotes deformation of the thecal sac with spinal cord abutment but without cord compression, grade 2 denotes spinal cord compression but with cerebrospinal fluid (CSF) visible around the cord, and grade 3 denotes spinal cord compression without CSF visible around the cord. An illustration of the ESCC scale is shown in [Figure 2](#fig2-2192568217694016){ref-type="fig"}. Using this classification, high-grade epidural disease (ESCC grade 2 or 3) is optimally managed with surgical decompression prior to SBRT to improve rates of local control while minimizing neurological complications.

![Schematic of the 6-point epidural spinal cord compression (ESCC) grading scale proposed by Bilsky et al.^[@bibr42-2192568217694016]^ The grade represented by each figure is denoted in the upper left hand corner of the figure. Grade of 0 denotes bone-only disease; 1a, epidural impingement, without deformation of the thecal sac; 1b, deformation of the thecal sac, without spinal cord abutment; 1c, deformation of the thecal sac with spinal cord abutment, but without cord compression; 2, spinal cord compression, but with CSF visible around the cord; and 3, spinal cord compression, no CSF visible around the cord.](10.1177_2192568217694016-fig2){#fig2-2192568217694016}

Spine SBRT Treatment Outcomes {#section5-2192568217694016}
=============================

Spine SBRT for De Novo Metastases {#section6-2192568217694016}
---------------------------------

Spine SBRT has been used effectively in many reported series in the setting of de novo spinal metastases, that is, in patients who have not received prior surgical intervention or radiotherapy. Given the lack of consensus on an ideal dose fractionation, a variety of regimens have been employed across different series. Local control ranges from 80% to 96% at 1 year, and pain response is generally achieved in the majority of patients although high-quality data is lacking. [Table 3](#table3-2192568217694016){ref-type="table"} summarizes selected recent representative series in which patients were treated with spine SBRT for de novo metastases. The results suggest superior outcomes with respect to local control when compared to cEBRT, for which reported control rates range from 61% to 86% at 1 year, but can be as low as 46% with mass-type tumors.^[@bibr43-2192568217694016][@bibr44-2192568217694016]--[@bibr45-2192568217694016]^ This is particularly notable when considering the inclusion of histologies traditionally deemed to be radioresistant such as melanoma, renal cell carcinoma, and sarcoma in SBRT studies. With respect to pain control, multiple systematic reviews have shown the overall pain response rate of conventional radiotherapy to be approximately 60% with a corresponding complete response rate ranging from 0% to 24%.^[@bibr46-2192568217694016][@bibr47-2192568217694016]--[@bibr48-2192568217694016]^ On the other hand, spine SBRT literature has reported complete response rates as high as 46% to 92%.^[@bibr49-2192568217694016][@bibr50-2192568217694016][@bibr51-2192568217694016]--[@bibr52-2192568217694016]^ Therefore, the data does suggest that while cEBRT may be reasonably efficacious in achieving partial pain relief, its efficacy may be inferior to that of spine SBRT when it comes to complete pain relief. It should be noted, however, that there is currently no completed randomized study comparing treatment outcomes from spine SBRT to those from conventional fractionation. An ongoing phase II/III RTOG study is randomizing patients with up to 3 separate sites of spinal metastases to 8 Gy in 1 fraction of cEBRT versus SBRT to a dose of 16 Gy or 18 Gy in a single fraction.^[@bibr53-2192568217694016]^ The feasibility of successfully delivering image-guided SBRT in this trial setting has been reported.^[@bibr54-2192568217694016]^ The primary objective of the phase III component of the study is to evaluate pain response rates as measured by the 11-point Numerical Rating Pain Scale (NRPS) at 3 months after study entry. More recently, a multi-center NCIC phase II randomized study has been launched which examines 20 Gy in 5 fractions of cEBRT versus SBRT to a dose of 24 Gy in 2 fractions.^[@bibr55-2192568217694016]^ It is anticipated that the results of these studies will provide higher quality outcome data with respect to spine SBRT in de novo metastases.

###### 

Selected Spine SBRT Series for Spinal Metastases With No Prior History of Radiation.

![](10.1177_2192568217694016-table3)

  Study Authors (Year)                                    Study Design    No. of Tumors/No. of Patients   No. of Postoperative Tumors   Histology              Total Dose (Range)/No. of Fractions (Range)                                  Follow-up in Months (Range)   Local Control                    Overall Survival                 Pain Response
  ------------------------------------------------------- --------------- ------------------------------- ----------------------------- ---------------------- ---------------------------------------------------------------------------- ----------------------------- -------------------------------- -------------------------------- ------------------------------------------------------
  Gerszten et al^[@bibr52-2192568217694016]^ (2007)       Prospective     156/na^a^                       9                             Mixed                  Mean: 20 Gy (12.5-25 Gy)/1                                                   Median: 21 (3-53)             90% (crude)                      na                               86% reported long-term improvement
  Yamada et al^[@bibr127-2192568217694016]^ (2008)        Retrospective   103/93                          0                             Mixed                  Median: 24 Gy (18-24 Gy)/1                                                   Median: 15 (2-45)             90% (15 months)                  Median: 15 months                na
  Sahgal et al^[@bibr59-2192568217694016]^ (2009)         Retrospective   23/14                           0                             Mixed                  Median: 24 Gy (7-40 Gy)/3 (1-5)                                              Median: 9 (1-26)              85% (1 year)/69% (2 years)       45% (2 years)                    na
  Nguyen et al^[@bibr49-2192568217694016]^ (2010)         Prospective     na/22^a^                        0^b^                          Renal cell carcinoma   Median: 27 Gy (24-30 Gy)/3 (1-5)                                             Median: 13.1 (3.3-54.5)       82% (1 year)^c^                  72% (1 year)^c^                  BPI: no pain 23% (baseline) to 52% (12 months)
  Wang et al^[@bibr76-2192568217694016]^ (2012)           Prospective     166/149                         0^d^                          Mixed                  27-30 Gy/3                                                                   Median: 15.9 (1.0-91.6)       80.5% (1 year)/72.4% (2 years)   68.5% (1 year)/46.4% (2 years)   BPI: no pain 26% (baseline) to 54% (6 months)
  Ahmed et al^[@bibr75-2192568217694016]^ (2012)          Retrospective   63/46^a^                        0                             Mixed                  Median: 24 Gy (10-40 Gy)/3 (1-5)                                             Mean: 8.2                     91.2% (1 year)                   59% (1 year)                     na
  Thibault et al^[@bibr128-2192568217694016]^ (2014)      Retrospective   60/37^a^                        10                            Renal cell carcinoma   Median: 24 Gy (18-30 Gy)/2 (1-5)                                             Median: 12.3 (1.2-55.4)       83.4% (1 year)/66.2% (2 years)   64.1% (1 year)/45.6% (2 years)   na
  Guckenberger et al^[@bibr74-2192568217694016]^ (2014)   Retrospective   387/301                         0                             Mixed                  Median: 24 Gy (10-60 Gy)/3 (1-20)                                            Median: 11.8 (0-105)          89.9% (1 year)/83.9% (2 years)   64.9% (1 year)/43.7% (2 years)   na
  Sohn et al^[@bibr129-2192568217694016]^ (2014)          Retrospective   13/13                           0                             Renal cell carcinoma   Mean: 38.0 Gy/median: 4                                                      na                            85.7% (1 year)                   Median: 15 months                23.1% complete; 53.8% partial
  Folkert et al^[@bibr73-2192568217694016]^ (2014)        Retrospective   108/88^a^                       33                            Sarcoma                Median: 24 Gy (18-24 Gy)/1 or median: 28.5 Gy (24-36 Gy)/3 (3-6)             Median: 12.3 (1-80.7)         87.9% (1 year)                   60.6% (1 year)                   na
  Park et al^[@bibr130-2192568217694016]^ (2014)          Retrospective   45/28^a^                        1                             Mixed                  Median: 27 Gy (18-35 Gy)/3 (1-5)                                             Median: 7.4 (1.1-42.5)        93.2% (1 year)/93.2% (2 years)   47.4% (1 year)/27.9% (2 years)   VAS: median 4 (pre-SBRT) to 1 (1-3 months post-SBRT)
  Anand et al^[@bibr50-2192568217694016]^ (2015)          Retrospective   76/52^e^                        8                             Mixed                  Median: 24 Gy (24-27 Gy)/3 (1-3)                                             Median: 8.5 (3.0-40.0)        94% (1 year)/82.6% (2 years)     68% (1 year)/45.4% (2 years)     92.3% complete; 5.8% partial
  Sellin et al^[@bibr131-2192568217694016]^ (2015)        Retrospective   40/37                           0                             Renal cell carcinoma   Median: 24 Gy (24-30 Gy)/1 (1-5)                                             Median: 49.0 (38.2-75.8)      57%                              Median: 16.3 months              VAS: 41.4% improved pain
  Bishop et al^[@bibr132-2192568217694016]^ (2015)        Retrospective   332/285^f^                      0                             Mixed                  Median (tumor dose): 43 Gy (biologically equivalent dose, alpha/beta = 10)   Median: 19 (0-111)            88% (1 year)/82% (3 years)       64% (1 year)/33% (3 years)       na
  Bate et al^[@bibr71-2192568217694016]^ (2015)           Retrospective   48/36^a^                        0                             Mixed                  16-23 Gy/1 or 20-30 Gy/2-5                                                   Median: 9.8                   95.8% (1 year)                   44% (crude)                      na
  Azad et al^[@bibr72-2192568217694016]^ (2015)           Retrospective   25/25                           0                             Mixed                  Median: 20 Gy (15-25.5)/2 (1-5)                                              Median: 18 (1-81)             84.2% (crude)                    Median: 28 months                na

Abbreviations: SBRT, stereotactic body radiotherapy; BPI, Brief Pain Inventory; VAS, 10-point Visual Analogue Scale; na, not available.

^a^Where available, re-irradiated lesions were removed from the total number of tumor count in each series.

^b^Twenty-eight of 48 patients from entire cohort (de novo and re-irradiated) underwent prior spine surgery.

^c^Data based on combined de novo and re-irradiation cases.

^d^Forty patients received prior radiotherapy alone, 22 patients received prior surgery alone, and 39 patients received prior radiotherapy and surgery.

^e^Four patients received prior radiotherapy.

^f^Includes both de novo and re-irradiated lesions but breakdown not reported.

Re-irradiation Spine SBRT {#section7-2192568217694016}
-------------------------

Repeat radiation treatment in the scenario of symptomatic bone metastases within the spine is a well-established practice for which the overall pain response rate with cEBRT is approximately 58% based on a meta-analysis of 7 studies.^[@bibr56-2192568217694016]^ A recent randomized study comparing 2 conventional fractionation schedules in the re-irradiation setting showed improved quality of life with less functional interference associated with pain in responders; however, a relatively low 11% to 14% complete pain response rate was observed in those patients who received their assigned treatment.^[@bibr57-2192568217694016],[@bibr58-2192568217694016]^ The challenge with re-irradiation has been in respecting the total biologically effective dose to the spinal cord. As a result, the dose given in the second course of radiation, with conventional techniques, is equal to or less than the initial course of cEBRT to limit spinal cord dose exposure. This practice is nonideal when the intent is to maximize local control. Spine SBRT is uniquely suited to this task with respect to re-irradiation as it allows dose escalation to the tumor while attaining rapid dose falloff to minimize spinal cord doses. Similar to the de novo situation, we expect greater rates of local control and complete pain response than conventional re-irradiation external beam radiotherapy.

Local control rates in re-irradiation spine SBRT reported in the literature range from 66% to 92% at 1 year; selected series are summarized in [Table 4](#table4-2192568217694016){ref-type="table"}. These numbers appear to be comparable to those achieved in de novo cases;^[@bibr59-2192568217694016]^ however, it is acknowledged given differences in patient, tumor, and treatment factors published in various de novo and retreatment cohorts, retrospective comparisons are only hypothesis-generating. A prospective cohort of 59 patients re-irradiated at the MD Anderson Cancer Center reported an actuarial 1-year local control and overall survival of 76% for both outcomes.^[@bibr60-2192568217694016]^ Freedom from neurologic deterioration from any cause was 92% at 1 year. High-quality pain response data unfortunately is limited within the literature in this population of patients; however, published series suggest overall response rates of 65% to 79%.^[@bibr61-2192568217694016][@bibr62-2192568217694016][@bibr63-2192568217694016]--[@bibr64-2192568217694016]^

###### 

Selected Re-Irradiation Spine SBRT Series for Spinal Metastases.

![](10.1177_2192568217694016-table4)

  Study Authors (Year)                                 Study Design    No. of Tumors/No. of Patients   Histology              Total Dose (Range)/No. of Fractions (Range)   Prior RT Dose (Range)/No. of Fractions (Range)                                                 Follow-up in Months (Range)   Local Control                    Overall Survival                       Pain Response
  ---------------------------------------------------- --------------- ------------------------------- ---------------------- --------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------- -------------------------------- -------------------------------------- -----------------------------------------------------
  Sahgal et al^[@bibr59-2192568217694016]^ (2009)      Retrospective   37/25                           Mixed                  Median: 24 Gy (7-40 Gy)/3 (1-5)               Median: 36 Gy/14                                                                               Median: 7 (1-48)              92% (1 year)                     45% (2 years)^a^                       na
  Mahadevan et al^[@bibr64-2192568217694016]^ (2010)   Retrospective   81/60                           Mixed                  Median: 24 Gy (24-30 Gy)/3 (3-5)              Median: 30 Gy (8-46 Gy)/10 (1-25)                                                              Median: 12 (4-36)             Median: 9 months                 Median: 11 months                      64.7% reported pain response; 18% complete response
  Choi et al^[@bibr61-2192568217694016]^ (2010)        Retrospective   51/42                           Mixed                  Median: 20 Gy (10-30 Gy)/2 (1-5)              Median: 40 Gy (30-40 Gy)/20 (10-20)                                                            Median: 7 (2-47)              73% (1 year)                     68% (1 year)                           65% reported pain response
  Garg et al^[@bibr60-2192568217694016]^ (2011)        Prospective     63/59                           Mixed                  Median: 27 Gy (20-30 Gy)/3 (3-5)              Median: 30 Gy/na                                                                               Median: 13 (0.9-67.5)         76% (1 year)                     76% (1 year)                           na
  Damast et al^[@bibr62-2192568217694016]^ (2011)      Retrospective   97/95                           Mixed                  Median: 30 Gy (16-30 Gy)/5 (4-6)              Median: 30 Gy (8-66 Gy)/na                                                                     Median: 12.1 (0.2-63.6)       66% (1 year)                     52-59% (1 year); median: 13.6 months   77% reported pain response
  Thibault et al^a,128^ (2014)                         Retrospective   11/37                           Renal cell carcinoma   Median: 24 Gy (18-30 Gy)/2 (1-5)              Median: 30 Gy (8-30 Gy)/10 (1-10)                                                              Median: 12.3 (1.2-55.4)       83.4% (1 year)/66.2% (2 years)   64.1% (1 year)/45.6% (2 years)         na
  Thibault et al^[@bibr65-2192568217694016]^ (2015)    Retrospective   56/40                           Mixed                  Median: 30 Gy (20-35 Gy)/4 (2-5)              Median (SBRT): 24 Gy (20-35 Gy)/2 (1-5); median (cEBRT, n = 24): 22.5 Gy (20-30 Gy)/5 (5-40)   Median: 6.8 (0.9-39)          80.6% (1 year)/71.5% (2 years)   48% (1 year)                           na
  Kawashiro et al^[@bibr63-2192568217694016]^ (2015)   Retrospective   23/23                           Mixed                  Median: 24.5 Gy (14.7-50 Gy)/5 (3-25)         Median: 30 Gy (30-40 Gy)/10 (10-20)                                                            Median: 10 (1-54)             88% (1 year)/75% (2 years)       50% (1 year)/20% (2 years)             78.9% reported pain relief

Abbreviations: SBRT, stereotactic body radiotherapy; na, not available.

^a^Data based on combined de novo and re-irradiation cases.

Specific to the setting of salvage SBRT, defined as imaging-confirmed local tumor progression at a previously radiation-treated site for which re-irradiation SBRT is offered, Sahgal et al reported an excellent local control rate of 96% at 1 year.^[@bibr59-2192568217694016]^ The management of failures after an initial course of SBRT and subsequent retreatment outcomes were largely unknown prior to the recent report by Thibault et al. The authors analyzed the outcomes specific to the management of SBRT failures with a salvage second course of spine SBRT,^[@bibr65-2192568217694016]^ in which 56 spinal segments in 40 patients were evaluated from a prospective database. The median salvage second SBRT dose fractionation was 30 Gy in 4 fractions. Overall survival and local control at 1 year were found to be 48% and 81%, respectively.

Postoperative Spine SBRT {#section8-2192568217694016}
------------------------

The role of decompressive surgery in patients with symptomatic single-level MESCC was established by Patchell et al.^[@bibr66-2192568217694016]^ This landmark article in the spine literature demonstrated the superiority of surgery and postoperative radiation over radiation as a standalone in the treatment of MESCC. Improvements in ambulatory status, neurologic status, and survival were shown in this practice defining randomized controlled trial. Moreover, in a recent multicenter, prospective study, Fehlings et al demonstrated that surgery, when combined adjunctively with radiation, improved quality of life outcomes as well as pain control and neurological status.^[@bibr67-2192568217694016]^

Traditionally, cEBRT has been the standard postoperative therapy as SBRT has only been recently developed. Local failure rates as high as 69.3% at 1 year have been reported and this prompted early adopters of SBRT to apply it to the postoperative indication.^[@bibr68-2192568217694016]^ Three larger series to date have reported on long-term outcomes of postoperative spine SBRT. Al-Omair et al reviewed 80 patients from a prospective database who were treated with surgery followed by postoperative SBRT to a median dose of 24 Gy in 2 fractions (44% treated with 18-26 Gy in 1 to 2 fractions, 56% treated with 18-40 Gy in 3 to 5 fractions) at the University of Toronto (UofT).^[@bibr69-2192568217694016]^ One-year local control and overall survival were 84% and 64%, respectively. Multivariate proportional hazards analysis showed the ability of patients to receive post-SBRT systemic therapy to be an important predictor of overall survival. Higher dose per fraction and the degree of epidural disease involvement as characterized by the Bilksy (ESCC) grade (1 or less) were significant predictors of local control. Furthermore, high-grade (ESCC grade 2 or 3) disease that was downgraded to 0 or 1 postoperatively had superior local control rates compared to those of postoperative grade 2 or higher. Laufer et al reported on 186 patients with MESCC treated at Memorial-Sloan Kettering Cancer Center with surgical decompression, instrumentation, and postoperative spine SBRT using a number of different dose fractionation schemes.^[@bibr70-2192568217694016]^ Durable local control was achieved with a rate similar to that of the UofT series at 83.6% at 1 year. High-dose hypofractionated SBRT, defined as 24 to 30 Gy in 3 fractions, was found to improve local control compared to low-dose hypofractionated SBRT, defined as 18 to 36 Gy in 5 or 6 fractions. This finding echoes the results of the UofT series where local control increases with total radiation dose. Bate et al reviewed 57 patients with 69 lesions treated with spine SBRT for spinal metastases, of which 48 lesions (70%) were treated with radiotherapy alone, and 21 (30%) were treated with surgery prior to radiation.^[@bibr71-2192568217694016]^ The rates of local control were excellent at 94.2% for all patients and 90.5% for those treated with surgery and postoperative SBRT at 1 year. The authors did not identify any statistically significant variables in predicting recurrence on univariate regression analysis. In all 3 series, adverse events were uncommon and the treatment procedures were well tolerated. [Table 5](#table5-2192568217694016){ref-type="table"} provides a summary of selected published postoperative spine SBRT series. Given the complexity of the patient population and rapid advances in the technology of SBRT delivery, prospective studies with higher quality health-related quality of life (HRQoL) data is currently unavailable. Notwithstanding, these important series have established the safety and efficacy of combining a surgical approach with postoperative SBRT.

###### 

Selected Postoperative Spine SBRT Series for Spinal Metastases.

![](10.1177_2192568217694016-table5)

  Study Authors (Year)                                  Study Design    No. of Tumors/No. of Patients   Histology   Total Dose (Range)/No. of Fractions (Range)                      Follow-up in Months (Range)   Local Control    Overall Survival                                            Pain Response
  ----------------------------------------------------- --------------- ------------------------------- ----------- ---------------------------------------------------------------- ----------------------------- ---------------- ----------------------------------------------------------- ---------------------------------
  Gerszten et al^[@bibr123-2192568217694016]^ (2005)    Prospective     26/26                           Mixed       Mean: 18 Gy to 80% isodose line (16-20 Gy)/1                     Median: 16 (11-24)            na               na                                                          VAS: 92% long-term improvement
  Rock et al^[@bibr133-2192568217694016]^ (2006)        Retrospective   18/18                           Mixed       Mean: 11.4 Gy (6-16)/1                                           Median: 7 (4-36)              na               na                                                          na
  Gerszten et al^[@bibr95-2192568217694016]^ (2009)     Prospective     11/11                           Mixed       Mean: 19 Gy (16-22.5 Gy)/1                                       Median: 11 (7-44)             na               na                                                          VAS: 100% long-term improvement
  Moulding et al^[@bibr134-2192568217694016]^ (2010)    Retrospective   21/21                           Mixed       Median: 24 Gy (18-24 Gy)/1                                       Median: 10.2 (1.2-54.0)       90.5% (1 year)   Median: 10.2 months                                         na
  Massicotte et al^[@bibr96-2192568217694016]^ (2012)   Retrospective   10/10                           Mixed       Median: 24 Gy (18-35 Gy)/3 (1-5)                                 Median: 13 (3-18)             70% (crude)      na                                                          na
  Al-Omair et al^[@bibr69-2192568217694016]^ (2013)     Retrospective   80/80                           Mixed       Median: 24 Gy (18-40 Gy)/2 (1-5)                                 Median: 8.3 (0.13-39.1)       84% (1 year)     64% (1 year)                                                na
  Laufer et al^[@bibr92-2192568217694016]^ (2013)       Retrospective   186/186                         Mixed       24 Gy/1 (21.5%) or 24-30 Gy/3 (19.9%), or 18-36 Gy/5-6 (58.6%)   Median: 7.6 (1.0-66.4)        83.6% (1 year)   29.0% (crude); median among patients who died: 6.1 months   na
  Bate et al^[@bibr71-2192568217694016]^ (2015)         Retrospective   21/21                           Mixed       16-22 Gy/1 or 20-30 Gy/2-5                                       Median: 13.7                  90.5% (1 year)   44%^a^ (crude)                                              na

Abbreviations: SBRT, stereotactic body radiotherapy; na, not available.

^a^Data based on combined SBRT alone and surgery + SBRT cases.

Toxicity of Spine SBRT {#section9-2192568217694016}
----------------------

In general, acute toxicity is mild and very limited in spine SBRT with 5% or less reported rates of severe and undesirable (grade 3 or higher) adverse events.^[@bibr69-2192568217694016][@bibr70-2192568217694016][@bibr71-2192568217694016][@bibr72-2192568217694016][@bibr73-2192568217694016][@bibr74-2192568217694016][@bibr75-2192568217694016]--[@bibr76-2192568217694016]^ Concerns regarding potential hardware failure as a result of postoperative spine SBRT have not been substantiated by the major series.^[@bibr69-2192568217694016][@bibr70-2192568217694016]--[@bibr71-2192568217694016]^ Laufer et al and Al-Omair et al reported 4 of 186 total treated (2.2%) cases and 1 of 51 instrumented (2.0%) cases of hardware failure, respectively. In fact, a small series has suggested a trend toward higher fusion rates and lower incidence of instrumentation failure with spine SBRT as compared to cEBRT;^[@bibr77-2192568217694016]^ however, larger prospective studies are lacking. It is important to note that the risk of a transient increase in pain during or shortly after SBRT, known as a pain flare, is nontrivial and in the order of 23% to 68%,^[@bibr78-2192568217694016],[@bibr79-2192568217694016]^ which may be ameliorated with the short-term use of dexamethasone.^[@bibr80-2192568217694016]^ A prospective observational study showed a pain flare incidence of 19% when patients were treated prophylactically with oral 4 mg or 8 mg of dexamethasone, implying a reduction in the incidence of pain flare from 68% in a previously reported steroid-naïve cohort.^[@bibr80-2192568217694016]^ Ultimately, a randomized controlled study would be required for definitive recommendations with respect to prophylactic steroid therapy.

Radiation-induced myelopathy, the most feared late complication, can be a serious and debilitating adverse event. Fortunately, in the modern era of spine SBRT, the occurrence of this complication is extremely rare. Sahgal et al analyzed the maximum point dose and to small volumes of the thecal sac and reported clear guidelines for spinal cord tolerance in the setting of both de novo irradiation and reirradiation.^[@bibr11-2192568217694016],[@bibr12-2192568217694016]^ Practitioners of spine SBRT are strongly recommended to consult these published guidelines in the planning and evaluation of radiation treatment.

A more common late effect of spine SBRT is radiation-induced VCF (an illustrative example is shown in [Figure 3](#fig3-2192568217694016){ref-type="fig"}). Early single institutional reports demonstrated crude risks of this complication from 11% to 39%.^[@bibr81-2192568217694016][@bibr82-2192568217694016]--[@bibr83-2192568217694016]^ In order to clarify the risk of VCF, a multi-institutional spine SBRT analysis based on 410 spinal segments was reported in 2013, in which the risk of the development of VCF was determined to be 14%.^[@bibr39-2192568217694016]^ VCF was defined as either a new (de novo) fracture or progression of an existing fracture. The median time to fracture was 2.5 months. A dose-complication relationship was observed such that patients treated with 24 Gy in 1 fraction had nearly a 40% risk of VCF. In general, doses ≥20 Gy per fraction must be used with great caution as they are associated with significantly higher risks of VCF. Preexisting risk factors should be taken into account in the overall management decision, as 3 of 6 SINS criteria including baseline VCF, lytic tumor, and spinal deformity have been identified in the multi-institutional study to be significant predictors of VCF. A recent post hoc analysis of 2 prospective cohorts confirms the utility of SINS as a predictive tool in this regard, demonstrating high SINS (7-12) as a statistically significant risk factor for VCFs and symptomatic fractures (hazard ratio 5.6 and hazard ratio 5.3, respectively).^[@bibr40-2192568217694016]^ Nonetheless, it is important to note that the data suggests only 50% of VCFs are symptomatic requiring any intervention, the majority of which will involve cement augmentation alone.

![Illustrative case of 61-year-old male patient with metastatic melanoma to T8 and L3 who was undergoing curative external beam radiation therapy for head and neck squamous cell carcinoma when he presented with mechanical back pain and right leg paresthesia along the L3 nerve root distribution. The diagnostic MRI shown in (A1-A2) demonstrated diffuse involvement of L3, a VCF with retropulsion, and extra osseous soft tissue extending into the anterior epidural space. The patient was treated with spine SBRT with minimal interruption to the head and neck cancer treatment with the target volume encompassing the entire vertebral body and bilateral posterior elements to a prescription dose of 24 Gy in 2 fractions, limiting the thecal sac to 18.7 Gy point max. Panel (B1-B2) illustrates the radiation plan in 2 planes, highlighting the tight isodose lines around the spinal canal with a rapid dose falloff gradient to limit exposure to normal tissues. Two and a half weeks after SBRT, the patient demonstrated fracture progression and underwent a posterior spinal decompression of circumferential disease, L3 vertebroplasty, and pedicle screw instrumentation L2 through L4, as shown in panel (C1-C2). Panel (D1-C2) indicates the hematoxylin and eosin stain and the SOX10 IHC, respectively, showing the tissue to be mostly reactive in nature with foamy histiocytes, hemorrhage, and multinucleated giant cells with only a few atypical nuclei in the background representing residual melanoma.](10.1177_2192568217694016-fig3){#fig3-2192568217694016}

Posttherapy Follow-up {#section10-2192568217694016}
=====================

Patterns of Failure {#section11-2192568217694016}
-------------------

Early published reports suggested that SBRT failures occur via 2 primary mechanisms: (1) marginal in the bone adjacent to the site of prior treatment and (2) in the epidural space adjacent to the spinal cord.^[@bibr84-2192568217694016],[@bibr85-2192568217694016]^ Al-Omair et al confirmed this finding in a detailed postoperative spine SBRT series where of the 21 failures, the most common site of progression was within the epidural space (71%).^[@bibr69-2192568217694016]^ A recent study evaluating the outcomes of salvage spine SBRT following in-field failure of initial SBRT also found 85% of progressors involved the epidural space, lending further support to the risk of failure in this area.^[@bibr65-2192568217694016]^ Furthermore, Al-Omair and colleagues showed that if baseline epidural disease is surgically downgraded then local control is improved.

This observation has now been shown by several investigators and could be a result of relative underdosing in the epidural space in order to respect the spinal cord dose tolerance, geographic miss, or tumor biology. Therefore, improving local control rates and reducing epidural progression rates may be achieved via one or more of the following strategies: (1) maximizing epidural disease resection to achieve optimal surgical downgrading, (2) increasing the allowable dose to the spinal cord considering that preliminary guidelines may be too conservative since our technique and imaging standards have improved dramatically from the early days of spine SBRT, and (3) combining SBRT with systemic therapy. These are all active areas of investigation.

Response Assessment {#section12-2192568217694016}
-------------------

Assessment of tumor and treatment response after SBRT is challenging given that no consensus guidelines exist as to the optimal method of determining radiologic and pain response. Considering imaging-based outcomes are increasing in importance with local control as a primary endpoint, we are only in the early phase of understanding MRI signal changes in the spine following high-dose SBRT, where evaluation may be further complicated by VCF or pseudoprogression, a phenomenon well-documented in brain glioma literature, which may be defined as subacute radiological appearance of tumor progression that subsequently subsides without further treatment and does not represent true progressive disease.^[@bibr86-2192568217694016]^ CT alone is inadequate in the assessment of spinal metastases when compared to MRI with significantly lower sensitivity (66.2% vs 98.5%). This is possibly due to the lack of malignant bone marrow replacement prior to the occurrence of osteoblastic or osteolytic changes in a proportion of cases.^[@bibr87-2192568217694016]^ The role of the CT, however, requires careful consideration given that MRI alone is unable to characterize blastic versus lytic lesions. Pain assessment may be complex in the spine, as an understanding of mechanical pain is required in addition to biologic tumor pain. Furthermore, patients often have multiple sites of spinal disease, which may be contributing to the symptomatic area. Therefore, determining the causal vertebral segment with respect to pain and documenting response is a major challenge.

A recent publication by the SPIne response assessment in Neuro-Oncology (SPINO) group has put forth suggested preliminary recommendations for imaging follow-up, follow-up frequency, and pain response evaluation based on the survey results from a panel of international experts in spine SBRT.^[@bibr88-2192568217694016]^ The preferred imaging modality for follow-up and tumor response assessment is MRI, T1- and T2-weighted axial non--contrast-enhanced sequences, ideally with a slice thickness of 1 to 2 mm. Gadolinium may be considered in select cases with extra-osseous extension into the paraspinal and/or epidural region. At the present time, T1- or T2-weighted signal changes posttherapy are to be interpreted with caution, and advanced MRI sequences such as diffusion-weighted imaging or DCE-MRI show promise but remain investigational. Validated criteria specifically designed for the assessment of radiographic tumor response in the spine have not yet been developed and the applicability of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in this setting is unfortunately limited. [Table 6](#table6-2192568217694016){ref-type="table"} summarizes the SPINO recommendations in image interpretation of tumor response and follow-up frequency. Spinal MRIs are recommended for follow-up every 2 to 3 months after SBRT for the first 12 to 18 months, and every 3 to 6 months thereafter. The first MRI should be done at 2 to 3 months after SBRT for response and toxicity assessment, especially considering the risk of VCF within this time frame.^[@bibr39-2192568217694016]^

###### 

Consensus SPINO Recommendations for Spine SBRT Response Assessment^[@bibr88-2192568217694016]^.

![](10.1177_2192568217694016-table6)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Imaging-based local tumor response
  MRI preferredImages should be interpreted by a radiation oncologist and radiologistLocal control may be defined as the absence of progression within the treated area on serial imaging (2 or 3 consecutive MRIs 6-8 weeks apart)Local progression may be defined as:Gross unequivocal increase in tumor volume or linear dimensionAny new or progressive tumor within the epidural spaceNeurological deterioration attributable to preexisting epidural disease with equivocal increased epidural disease dimensions on MRIPseudoprogression and necrosis should be considered, with repeat imaging and biopsy to confirm when in doubtRECIST criteria are not optimum to monitor response in spinal metastases treated with SBRT, and consensus criteria for imaging-based tumor response are needed
  Pain response
  BPI preferred, with assessment based on worst pain scoreInternational Consensus Pain Response Endpoints (ICPRE) should be adopted as standard guidelines for pain responsePain response should be assessed at 3 months after SBRT
  Imaging follow-up frequency
  Spine MRI every 2 to 3 months after SBRT for the first 12 to 18 months, and every 3 to 6 months thereafter
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: SPINO, SPIne response assessment in Neuro-Oncology group; SBRT, stereotactic body radiotherapy; MRI, magnetic resonance imaging; RECIST, Response Evaluation Criteria in Solid Tumors; BPI, Brief Pain Inventory.

Evaluation of pain response requires a validated pain assessment instrument such as the Brief Pain Inventory, and an appropriately chosen time point as the endpoint of interest, most commonly at 3 months after SBRT administration. The International Bone Metastases Consensus Working Party has outlined formal criteria with respect to endpoints in palliative radiotherapy specific to bone metastases.^[@bibr89-2192568217694016],[@bibr90-2192568217694016]^

Surgical Approach to Spinal Metastases {#section13-2192568217694016}
======================================

Surgical indications in a patient with spinal metastases include preservation or restoration of neurologic function, reduction in intractable tumor-related pain, spinal stabilization, and tumor control in select cases.^[@bibr91-2192568217694016],[@bibr92-2192568217694016]^ In general, experts agree that appropriate candidates should have a life expectancy of at least 3 months. Complex patients warrant thorough consideration in a multidisciplinary setting involving the surgeon, radiation oncologist, and medical oncologist.^[@bibr93-2192568217694016]^

Prior to the use of radiotherapy for MESCC, simple laminectomy, which entailed removal of the posterior elements of the spinal column, was the only available treatment, but this failed to demonstrate any benefit over that of conventional radiation alone.^[@bibr94-2192568217694016]^ Moreover, simple laminectomy used without instrumentation carries the risk of creating spinal instability. The subsequent development of direct decompressive surgery, often combined with reconstruction to provide stabilization culminated in the landmark Patchell randomized trial demonstrating the superiority of surgery plus cEBRT over that of cEBRT alone with respect to patients' ability to walk post treatment (84% vs 57%), the duration of time over which ambulation was retained (median 122 days vs 13 days), and the percentage of patients regaining the ability to walk who were nonambulatory prior to therapy (62% vs 19%).^[@bibr66-2192568217694016]^ The need for opioid analgesics and corticosteroids was also reduced in the surgery plus radiation group compared to that of the radiation alone group. More recently, Fehlings et al reported on both clinical-assessed criteria and patient-reported functional and health-related quality of life outcomes following surgical intervention in these patients in a major prospective trial led by the AOSpine North American Clinical Research Network.^[@bibr67-2192568217694016]^ This multicenter observational cohort study evaluated 142 patients with a single symptomatic MESCC lesion who were treated surgically for intractable pain (38.7%), neurological deficits (40.2%), and/or imminent or overt spinal instability (21.1%). The surgeries involved a median of 5 vertebral levels with spinal construction using spinal devices performed in 134 patients (94.4%). Postoperative radiotherapy was considered for all patients and deemed beneficial and administered in 121 patients (85.2%). The results showed a median survival of 7.7 months, and 30-day and 12-month morality rates of 9% and 62%, respectively. The incidence of wound complications was 10%. Statistically significant improvements were seen in ambulatory status at 6 months, in Oswestry Disability Index, EQ-5D, and pain interference at 6 weeks and at 3, 6, and 12 months. The American Spinal Injury Association impairment scale grade also improved at 3 months after surgery. SF-36 Short Form Health Survey improved postoperatively in 6 of 8 scales. This was the largest study to date to provide high-quality prospective HRQoL outcomes in patients with MESCC, and offers favorable evidence for surgical intervention including spinal reconstruction, as an adjunct to radiation and chemotherapy to achieve prompt and sustained pain relief, and improvements in neurologic, functional, and HRQoL outcomes in this population of patients with at least a 3-month life expectancy and a single focal lesion causing MESCC. As new surgical instrumentation and techniques have emerged, a wider spectrum of interventions have become available to patients.^[@bibr95-2192568217694016][@bibr96-2192568217694016][@bibr97-2192568217694016]--[@bibr98-2192568217694016]^

Surgical Techniques {#section14-2192568217694016}
-------------------

Traditional open surgery may require extensive soft tissue exposure, and an anterior, posterior, lateral, or combined approach may be undertaken. The choice of approach depends on multiple factors such as tumor location, reconstruction options, and the optimal route of access. Tumors most often arise anteriorly within the vertebral body and subsequently extend posteriorly. Therefore, anterior approach commonly provides the most direct access. On the other hand, the posterior approach is more familiar to most surgeons and avoids the morbidity of an anterior approach. A simultaneous anterior-posterior approach may be utilized in cases where the tumor involves both the anterior and posterior columns as it facilitates direct visualization of adjacent neurovascular structures, the ability to perform a complete resection, and the placement of ventral and dorsal stabilization hardware in one session.^[@bibr99-2192568217694016]^ However, a combined approach is more extensive and rarely performed for metastatic disease. Irrespective of the approach, circumferential decompression of the spinal cord is the key element. As those surgeries can be destabilizing, reconstruction is critical. Multiple studies have shown the benefit of decompressive surgery combined with stabilization in terms of improved pain, neurologic function, and quality of life.^[@bibr66-2192568217694016],[@bibr100-2192568217694016][@bibr101-2192568217694016][@bibr102-2192568217694016][@bibr103-2192568217694016][@bibr104-2192568217694016]--[@bibr105-2192568217694016]^ A number of reconstruction instrumentation systems have been used in practice. In this population where life expectancy is limited, reconstruction of the anterior column is often performed with polymethylmethacrylate (PMMA). This option is inexpensive and offers immediate stability. Cages and auto/allograft are usually reserved when long-term survival is anticipated. Posteriorly, stabilization usually involves multilevel point of fixation using a screw-rod system.^[@bibr106-2192568217694016]^

Some tumors are hypervascular and as the tumor capsule is violated to accomplish surgical decompression, significant blood loss can be expected. To minimize blood loss, preoperative embolization may be considered for vascular malignancies such as renal cell carcinoma, thyroid carcinoma, and hepatocellular carcinoma. Early case series supported the practice of preoperative embolization and its benefit of reducing the risk of intraoperative hemorrhage in hypervascular tumors, particularly of renal cell origin.^[@bibr107-2192568217694016],[@bibr108-2192568217694016]^ A randomized controlled trial of 45 patients reported in 2015 showed no overall statistically significant difference in intraoperative blood loss and allogeneic red blood cell transfusion between the arms assigned to preoperative embolization and preoperative angiography only (control).^[@bibr109-2192568217694016]^ The validity of their results may be limited by the fact that no corpectomy/anterior decompression was performed, which is the part of the surgery where most blood loss is encountered. Even with this limitation, a subgroup analysis did demonstrate a significant decrease in blood loss in the embolization arm in moderate and pronounced hypervascular tumors as graded based on angiography. Furthermore, surgery time was significantly shorter in the embolization group.

As a cautionary note, surgery for spinal metastases can be associated with significant morbidity, underscoring the importance of proper patient selection. Lau et al reported an overall complication rate of 21.7% in a cohort of 106 patients who underwent surgery for spinal metastasis.^[@bibr110-2192568217694016]^ Predictors for higher rates of complication included age \>40 and metastatic lesion involving 3 or more contiguous levels. Jansson et al reported a similar rate of complication of 20% in a series of 282 patients.^[@bibr111-2192568217694016]^ A systematic review of the literature from 1970 to 2007 showed an overall complication rate of 29% and a 30-day mortality rate of 5%. In a prospective study of the general spine population, Street et al observed a mean of 3.1 and 4.7 adverse events (AEs) per patient for the elective and emergency oncologic population, respectively.^[@bibr112-2192568217694016]^ More recently, using the same prospective database but only focusing on the emergent oncologic population, Dea et al reported that 76.2% of the patients experienced at least one AE and intraoperative AE occurred in 32% of the patients.^[@bibr113-2192568217694016]^ Mortality within the same admission was 10.9%. This data emphasized that patient counseling and selection is primordial.

Minimally Invasive Spine Surgery (MISS) and Percutaneous Augmentation Procedures {#section15-2192568217694016}
--------------------------------------------------------------------------------

The guiding principle behind MISS is minimization of injury to the normal anatomy without negatively affecting the ability to address the patient's specific pathology. MISS, using tubular retraction techniques, were initially applied to spinal stenosis, disc herniation, and pedicle screw fixation;^[@bibr114-2192568217694016]^ however, applications are now being increasingly seen in the setting of spinal malignancies. Molina et al performed a systematic review of MISS in the management of metastatic spine disease, which included 5 studies addressing the use of video-assisted thoracotomy (VAST) or endoscopy-assisted posterior decompression, and 6 studies addressing the use of minimal access spine surgery (MASS).^[@bibr115-2192568217694016]^ VAST and MASS techniques both yielded similar results in achieving pain and neurologic dysfunction relief, but the data suggested that MASS may be associated with lower operative times, shorter hospital stay, and decreased blood loss; however, it was uncertain if these differences were statistically significant. Miscusi et al reviewed 2 series of patients treated at the same institution with one group having undergone standard open surgery and the other MISS for acute myelopathy secondary to spine metastases and showed no significant differences between the 2 groups with regard to neurological outcomes and complications.^[@bibr116-2192568217694016]^ Furthermore, the MISS cohort demonstrated reduced blood loss, shorter operative time and bed rest length, which was associated with more rapid functional recovery and discharge from hospital. One of the earliest series combining MASS and postoperative spine SBRT was described by Massicotte et al, where the surgical technique was based on a tubular retraction system and stabilization achieved using methylmethacrylate applied under direct visualization.^[@bibr96-2192568217694016]^ Decompression of the thecal sac was attained in 8 of 10 cases and intraoperative blood loss was minimal. Local control based on imaging with a median follow-up of 13 months was 70%. Improvements were observed in pain control, disability, and quality of life.

"Separation surgery" refers to a limited approach where only the epidural component of the tumor is decompressed and stabilization is achieved to facilitate postoperative radiation. It allows for high-dose radiation to be delivered with minimal risk to the spinal cord. Fixation is typically percutaneous with screws 2 levels above and 2 levels below the affected level, and decompression performed through a limited approach. Amankulor et al reviewed 318 patients who underwent posterolateral decompressive surgery and posterior segmental instrumentation without anterior column reconstruction to assess the incidence of symptomatic hardware failure.^[@bibr117-2192568217694016]^ The authors found 9 (2.8%) cases of symptomatic hardware failure and identified prior chest wall resection and construct lengths spanning 6 or more contiguous vertebral segments as risk factors for failure. The data suggests that "separation surgery" offers an effective treatment. A novel approach to managing tumors within the epidural space that has recently been reported is laser interstitial thermotherapy (LITT).^[@bibr118-2192568217694016][@bibr119-2192568217694016]--[@bibr120-2192568217694016]^ The procedure entails CT-image guided placement of laser catheters via a lateromedial transpedicular trajectory at a distance of 5 to 6 mm from the dural edge. Thermal ablation of tumor is performed under real-time monitoring using thermal MRI up to a threshold of 50°C at the interface of the tumor and dura to avoid damage to the neural elements. Subtraction of the nonenhancing tissue from the pre- and postcontrast images allows direct estimation of the area of coagulative necrosis immediately after treatment. In combination with postprocedure spine SBRT, this procedure has been shown to be feasible and in a preliminary study of 11 patients, in whom pain reduction and downgrading of ESCC scale were demonstrated.^[@bibr120-2192568217694016]^ The median hospital stay was 2 days and 1 case of transient limb paresthesia was observed, which resolved after 4 weeks. These early reports suggests that LITT combined with postprocedure spine SBRT may represent a potential alternative to "separation surgery" in patients without neurological deficits prior to SBRT, particularly in cases where conventional surgery may be morbid and lead to prolonged delays in the delivery of subsequent oncological treatments. However, higher quality prospective data is required to establish the safety and efficacy of this approach.

Vertebroplasty and kyphoplasty are conservative techniques wherein cement, most commonly PMMA, is injected into the vertebral body via a percutaneous needle under fluoroscopy guidance. Kyphoplasty differs from vertebroplasty in that an inflatable balloon is first employed to create a cavity into which cement may be administered with the goal of restoring vertebral body height. PMMA provides structural support to maintain anterior column stability, and in patients who have symptomatic VCFs, kyphoplasty has been shown to improve pain and back-specific functional status in a randomized study.^[@bibr98-2192568217694016]^ Fourney et al reported in a series of 56 patients marked or complete pain relief in 84% of those who underwent vertebroplasty or kyphoplasty.^[@bibr121-2192568217694016]^ Asymptomatic cement extravasation was observed in 9.2% of the vertebroplasty cohort and none in the kyphoplasty cohort. In general, cement leakage beyond the vertebral body is uncommon and typically does not require further intervention. Based on available evidence, the Spine Oncology Study Group endorsed a strong recommendation for cement augmentation in patients with painful compression fractures due to metastatic spine disease.^[@bibr122-2192568217694016]^ The efficacy and safety of a combined approach with kyphoplasty followed by spine SBRT has also been reported.^[@bibr123-2192568217694016]^ However, in select cases with epidural disease the possibility of tumor extravasation must be taken into account as it has been recently illustrated by Cruz et al.^[@bibr124-2192568217694016]^ Of note, in the setting of mechanical instability secondary to tumor involvement, especially in the presence of posterior element fractures (pedicles and/or joints), vertebroplasty or kyphoplasty alone may be insufficient to provide vertebral column support. In such cases, percutaneous pedicle screw fixation alone or a combinatorial approach with screw fixation and cement augmentation may be appropriate.^[@bibr125-2192568217694016],[@bibr126-2192568217694016]^ In the series reported by Moussazadeh et al, 44 patients underwent cement-augmented percutaneous spinal fixation with a median SINS of 10 (range 8-15), and complete pain resolution was observed in 29 (66%) patients.^[@bibr126-2192568217694016]^ Complications were limited with one adjacent-level fracture responsive to kyphoplasty and one case of asymptomatic screw pullout.

Conclusion {#section16-2192568217694016}
==========

The optimal management of patients with spinal metastases is complex and requires multidisciplinary assessment from an oncologic team that is familiar with the shifting paradigm as a consequence of evolving techniques in surgery and stereotactic radiation, as well as new developments in systemic agents. SINS and the ESCC (Bilsky) grading systems are useful tools that facilitate communication among oncologic team members and can direct management by providing a baseline assessment of risks prior to therapy. Spine SBRT is a highly effective treatment that is capable of delivering ablative doses to the target while sparing the critical organs-at-risk, chiefly the critical neural tissues, within a short and manageable schedule. At the same time, surgery occupies an important role in select patients, particularly with the expanding availability and expertise in minimally invasive techniques. The combined multimodality approach with "separation surgery" followed by postoperative spine SBRT achieves thecal sac decompression, improves tumor control, and avoids complications that may be associated with more extensive surgery. With rapid adoption of spine SBRT in centers outside of the academic setting, it is imperative for the practicing oncologist to understand the relevance and application of these evolving concepts.
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